Tag Archives: outperform

2026 Weight Loss Drug Set to Outperform Ozempic and Zepbound: What You Need to Know

Posted on by
Reply

Innovative Weight Loss Treatments

Achieving a Healthy Weight: A Future of Possibilities

Merch Hub/Shutterstock

Recent advancements in obesity treatments have introduced highly effective medications, with the prospect of even more potent experimental treatments set for testing in 2026.

“We are witnessing an ambitious new phase in obesity treatment that promises improved health outcomes for numerous patients,” states Laura Heisler from the University of Aberdeen, UK. “Obesity is linked to severe health complications, including cancer, heart disease, and type 2 diabetes. A modest 5% reduction in body weight can significantly decrease these health risks.”

The first major weight loss drug, semaglutide, was initially approved as a diabetes treatment in 2017 under the name Ozempic. In 2021, it received approval for weight management as Wegovy.

Semaglutide functions by imitating the natural hormone GLP-1, which binds to brain and pancreatic receptors, helping to curb appetite and slow gastric emptying. Alongside its weight loss benefits, semaglutide has demonstrated positive cardiovascular effects and potential in managing conditions like substance addiction. However, common side effects like nausea can lead to discontinuation of the drug.

In 2023, Tirzepatide, marketed as Mounjaro for diabetes, secured approval for weight loss under the name Zepbound. Enhancing semaglutide’s effectiveness, Tirzepatide operates by mimicking both GLP-1 and another hormone, GIP, which is involved in energy management. Like semaglutide, it has comparable side effects.

In clinical trials, semaglutide resulted in an average weight reduction of 14% over 72 weeks, while participants using tirzepatide achieved a 20% reduction. Notably, regaining lost weight is common once the medication is stopped.

Looking ahead, more dual-action and even triple-action medications are in development. A promising candidate for 2024 approval is Kaglisema, which merges semaglutide with Caglilintide, a drug that stimulates fullness through amylin mimicry.

In a trial with over 3,400 adults, those taking Kaglisema achieved a weight loss of 20% after 68 weeks, outperforming both semaglutide (15%) and Caglilintide alone (12%), indicating strong potential.

Additionally, a drug named amicretin is undergoing development. Similar to CagliSema, it mimics both GLP-1 and amylin, but uses a single molecule that binds to both receptor types.

In preliminary trials involving 125 participants, amicretin users experienced an average weight loss of 24% after 36 weeks, suggesting superior effectiveness compared to tirzepatide, although final-stage trials won’t commence until 2026.

Moreover, the “triple G” drug letartortide activates three hormones to facilitate fat release: GLP-1, GIP, and glucagon. In a study of 338 individuals, those on the highest dose experienced an average weight loss of 24% after 48 weeks. Results from late-stage trials will be crucial for assessing letartortide’s approval timeline, expected in late 2026 or beyond.

It’s important to note that weight loss results from various clinical studies aren’t directly comparable due to differences in participant criteria, study durations, and dosages. Moreover, average results can mask significant variability in individual responses to GLP-1 drugs; while some experience negligible effects, others see remarkable weight loss.

As many as 100 new weight-loss drugs are currently in development for 2026 and beyond as companies strive to capture a share of the lucrative market. These innovations often focus on diverse combinations of existing targets, such as GLP-1, GIP, glucagon, and amylin receptors, or explore new mechanisms entirely.

Research is also addressing adverse effects, such as the evidence indicating some weight loss from GLP-1 drugs may come from muscle rather than fat. For instance, a recent trial earlier this year combined semaglutide with bimagrumab, a muscle growth inhibitor, seeking to counterbalance these effects.

“The prospect of emergent, highly effective drugs with fewer side effects is indeed exciting,” says Heisler.

Topics:

This optimization enhances the SEO value by incorporating relevant keywords, improving clarity, and ensuring the content is structured effectively while maintaining existing HTML tags.

Source: www.newscientist.com

Microsoft Claims AI Systems Outperform Doctors in Diagnosing Complex Health Conditions

Posted on by
Reply

Microsoft is unveiling details about artificial intelligence systems that outperform human doctors in intricate health assessments, paving a “path to medical closeness.”

The company’s AI division, spearheaded by British engineer Mustafa Suleyman, has created a system that emulates a panel of specialized physicians handling “diagnostically complex and intellectually demanding” cases.

When integrated with OpenAI’s advanced O3 AI model, Microsoft claims its method “solved” more than eight out of ten carefully selected case studies for diagnostic challenges. In contrast, practice physicians with no access to colleagues, textbooks, or chatbots achieved an accuracy rate of only 2 out of 10 on these same case studies.

Microsoft also highlighted that this AI solution could be a more economical alternative to human doctors, as it streamlines the process of ordering tests.

While emphasizing potential cost reductions, Microsoft noted that it envisions AI as a complement to physician roles rather than a replacement.

“The clinical responsibilities of doctors extend beyond merely diagnosing; they must navigate uncertainty in ways that AI is not equipped to handle, and build trust with patients and their families,” the company explained in a blog post announcing the research intended for peer review.

Nevertheless, slogans like “The Road to Overmed Medical” hint at the possibility of transformative changes in the healthcare sector. Artificial General Intelligence (AGI) denotes systems that replicate human cognitive abilities for specific tasks, while superintelligence is a theoretical concept referring to systems that surpass overall human intellectual capacity.

In discussing the rationale for their study, Microsoft raised concerns about AI’s performance on U.S. medical licensing exams, a crucial assessment for acquiring medical licenses in the U.S. The multiple-choice format relies heavily on memorization, which may “exaggerate” AI capabilities compared to in-depth understanding.

Microsoft is working on a system that mimics real-world clinicians by taking step-by-step actions to arrive at a final diagnosis, such as asking targeted questions or requesting diagnostic tests. For instance, patients exhibiting cough or fever symptoms may need blood tests and chest x-rays prior to receiving a pneumonia diagnosis.

This innovative approach by Microsoft employs intricate case studies sourced from the New England Journal of Medicine (NEJM).

Suleyman’s team transformed over 300 of these studies into “interactive case challenges” to evaluate their method. Microsoft’s strategy incorporated existing AI models developed by ChatGPT creators OpenAI, Meta from Mark Zuckerberg, Anthropic, Grok from Elon Musk, and Google’s Gemini.

The company utilized a specific model for determining tests and diagnostics, employing AI systems such as tailored agents known as “diagnostic orchestrators.” These orchestrators effectively simulate a doctor’s panel, aiding in reaching a diagnosis.

Microsoft reported that in conjunction with OpenAI’s advanced O3 model, over eight of the ten NEJM case studies have been “solved.”

Microsoft believes its approach has the potential to encompass multiple medical fields, enabling a broad and in-depth application beyond individual practitioners.

“Enhancing this level of reasoning could potentially reform healthcare. AI can autonomously manage patients with routine care and offer clinicians sophisticated support for complex cases.”

However, Microsoft acknowledges that the technology is not yet ready for clinical implementation, noting that further testing with an “Orchestrator” is necessary to evaluate performance in more prevalent symptoms.

Source: www.theguardian.com

Men outperform women in navigation skills, but it’s not due to evolutionary factors

Posted on by
Reply

If men were encouraged to play outside as children, they may have better navigation skills than women

Colin Hawkins/Getty Images/Image Source

In fact, men tend to have a better sense of direction than women, but this is probably due to differences in upbringing rather than improved navigational skills being an evolutionary trait.

In previous research, Men slightly outperform women on spatial navigation tasks. Some researchers believe this is due to evolution, since in prehistoric times it was common for men to travel long distances to hunt, while women often stayed close to home. It suggests that it is. This may have resulted in selection pressure on men to develop advanced navigation skills.

But if that were the case, she says, those genes would be passed on to female offspring, as long as they're not on the Y chromosome. Justin Rose At the University of Illinois at Urbana-Champaign. “The really obvious alternative is culture,” he says. “It plays a huge role in what men and women experience.”

For example, boys may be encouraged to play outside more than girls, which may help hone their navigation skills, he says.

To investigate this idea, Rose and his colleagues collected data from 21 species of animals, including humans. This data includes information about their spatial navigation skills and how far they travel on average from home.

If natural selection were at work, we would expect males and females that traveled farther from home to have better navigational abilities, and this is consistent across species.

Instead, the researchers found that males of all species are slightly better at navigating than females, although in some species, such as the rusty crayfish (Faxonius rusticus) and the little devil poison dart frog (Uofaga Silvatica), females had a wider home range.

This finding suggests that differences in navigation between men and women may be cultural. It could also be a side effect of biological differences between males and females, as well as between male and female animals. For example, hormonal differences “can affect all kinds of traits,” Rose says. As long as those traits don't prevent reproduction, “evolution doesn't matter,” he says.

In previous spatial navigation research, There were no differences in these skills between men and women from similar backgrounds.

“The authors show in a very comprehensive way that sex differences in spatial ability are likely acquired, for example through culture.” Antoine Cutolo At the French National Center for Scientific Research. “Spatial skills are much like other cognitive skills: the more you use them, the better you become at them.”

topic:

Source: www.newscientist.com